» Articles » PMID: 22570563

Efficacy Profile of Liposome Bupivacaine, a Novel Formulation of Bupivacaine for Postsurgical Analgesia

Overview
Journal J Pain Res
Publisher Dove Medical Press
Date 2012 May 10
PMID 22570563
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Liposome bupivacaine is a novel formulation of the local anesthetic bupivacaine, designed to provide prolonged postsurgical analgesia. This analysis examined pooled efficacy data as reflected in cumulative pain scores from 10 randomized, double-blind liposome bupivacaine clinical studies in which the study drug was administered via local wound infiltration.

Methods: A total of 823 patients were exposed to liposome bupivacaine in 10 local wound infiltration studies at doses ranging from 66 mg to 532 mg in five surgical settings; 446 patients received bupivacaine HCl (dose: 75-200 mg) and 190 received placebo. Efficacy measures were assessed through 72 hours after surgery.

Results: Overall, 45% of patients were male and 19% were ≥65 years of age. In the analysis of cumulative pain intensity scores through 72 hours, liposome bupivacaine was associated with lower pain scores than the comparator in 16 of 19 treatment arms assessed, achieving statistically significant differences compared with bupivacaine HCl (P < 0.05) in five of 17 treatment arms. These results were supported by results of other efficacy measures, including time to first use of opioid rescue medication, proportion of patients avoiding opioid rescue medication, total postsurgical consumption of opioid rescue medication, and patient/care provider satisfaction with postoperative analgesia. Local infiltration of liposome bupivacaine resulted in significant systemic plasma levels of bupivacaine, which could persist for 96 hours; systemic plasma levels of bupivacaine following administration of liposome bupivacaine were not correlated with local efficacy. Liposome bupivacaine and bupivacaine HCl were generally well tolerated.

Conclusion: Based on this integrated analysis of multiple efficacy measures, liposome bupivacaine appears to be a potentially useful therapeutic option for prolonged reduction of postsurgical pain in soft tissue and orthopedic surgeries.

Citing Articles

Liposomal Bupivacaine Use in Third Molar Impaction Surgery: INNOVATE Study.

Lieblich S, Danesi H Anesth Prog. 2024; 71(4):199-207.

PMID: 39711449 PMC: 11614472. DOI: 10.2344/333161.


A prospective, randomized trial of liposomal bupivacaine compared to conventional bupivacaine on pain control and postoperative opioid use in adults receiving adductor canal blocks for total knee arthroplasty.

Quaye A, McAllister B, Garcia J, Nohr O, Laduzenski S, Mack L Arthroplasty. 2024; 6(1):6.

PMID: 38297390 PMC: 10832097. DOI: 10.1186/s42836-023-00226-y.


Liposomal bupivacaine versus conventional anesthetic or placebo for hemorrhoidectomy: a systematic review and meta-analysis.

Solis-Pazmino P, Figueroa L, La K, Termeie O, Oka K, Schleicher M Tech Coloproctol. 2024; 28(1):29.

PMID: 38294561 PMC: 10830612. DOI: 10.1007/s10151-023-02881-4.


Effectiveness of a Novel Temperature-Responsive Hydrogel (PF72) for Postoperative Pain Relief in Breast Augmentation.

Cho J, Kim K, Lee W, Young Go J, Kim S J Clin Med. 2024; 13(1).

PMID: 38202117 PMC: 10779951. DOI: 10.3390/jcm13010110.


Evaluating the Efficacy of Liposomal Bupivacaine in Postoperative Pain Management for Rhinoplasty: A Retrospective Study.

Alameddine K, Richards B, Vyas K, Chaudhry A, Millesi E, Hamilton G Aesthetic Plast Surg. 2023; 48(9):1722-1727.

PMID: 37775576 DOI: 10.1007/s00266-023-03656-w.


References
1.
Beauregard L, Pomp A, Choiniere M . Severity and impact of pain after day-surgery. Can J Anaesth. 1998; 45(4):304-11. DOI: 10.1007/BF03012019. View

2.
Jirasiritham S, Tantivitayatan K, Jirasiritham S . Perianal blockage with 0.5% bupivacaine for postoperative pain relief in hemorrhoidectomy. J Med Assoc Thai. 2004; 87(6):660-4. View

3.
White P . Multimodal analgesia: its role in preventing postoperative pain. Curr Opin Investig Drugs. 2008; 9(1):76-82. View

4.
Mahabir R, Peterson B, Williamson J, Valnicek S, Williamson D, East W . Locally administered ketorolac and bupivacaine for control of postoperative pain in breast augmentation patients. Plast Reconstr Surg. 2004; 114(7):1910-6. DOI: 10.1097/01.prs.0000142996.50331.2c. View

5.
Moiniche S, Kehlet H, Dahl J . A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief: the role of timing of analgesia. Anesthesiology. 2002; 96(3):725-41. DOI: 10.1097/00000542-200203000-00032. View